These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22258336)

  • 21. Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients.
    Olivieri O; Pizzolo F; Ciacciarelli A; Corrocher R; Signorelli D; Falcone S; Blengio GS
    Am J Hypertens; 2008 Sep; 21(9):976-82. PubMed ID: 18600211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antihypertensive therapy for refractory morning hypertension in patients on peritoneal dialysis].
    Kuriyama S; Otsuka Y; Iida R; Kobayashi S; Yamagishi H; Hosoya T
    Nihon Jinzo Gakkai Shi; 2005; 47(1):38-45. PubMed ID: 15754762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Monogenic hypertension].
    Bähr V; Oelkers W; Diederich S
    Med Klin (Munich); 2003 Apr; 98(4):208-17. PubMed ID: 12715144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic Issues in treating hypertension in CKD.
    Sica DA
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):42-7. PubMed ID: 21224029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary aldosteronism: are we missing the wood for the trees?
    Funder JW
    Horm Metab Res; 2012 Mar; 44(3):251-3. PubMed ID: 22281545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
    Gullapalli N; Bloch MJ; Basile J
    Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.
    Schrier RW; Masoumi A; Elhassan E
    Clin J Am Soc Nephrol; 2010 Jun; 5(6):1132-40. PubMed ID: 20448074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hypertension in patients with diabetes].
    Poulsen PL; Hansen KW; Gaede PH; Rossing P
    Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical role of direct renin inhibition in hypertension.
    Taylor AA; Pool JL
    Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldosteronism and hypertension.
    Calhoun DA
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1039-45. PubMed ID: 17699324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cutoff value of aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine.
    Niizuma S; Nakahama H; Kamide K; Fukuchi K; Iwanaga Y; Nakata H; Yoshihara F; Horio T; Nakamura S; Kawano Y
    Clin Exp Hypertens; 2008 Oct; 30(7):640-7. PubMed ID: 18855267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.
    Glicklich D; Frishman WH
    Drugs; 2015 Apr; 75(5):473-85. PubMed ID: 25787734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.